Skip to content

X4 Pharmaceuticals, Inc

XFOR

CIK 0001501697

← back to feed
Revenue (TTM)
$35.25M
+1,273.2% YoY Q1 May 2026
Net Income (TTM)
−$75.52M
−111.5% YoY Q1 May 2026
EPS Diluted (TTM)
−$4.28
+66.5% YoY Q1 May 2026
Gross Margin
83.0%
Q1 May 2026
Operating Margin
-236.8%
Q1 May 2026
Net Margin
-214.2%
Q1 May 2026
Free Cash Flow (TTM)
−$129.79M
Q1 May 2026
Cash
$216.91M
Q1 May 2026
Total Debt
$54.57M
Q1 May 2026
Shares Outstanding
94.32M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings